arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Larimar Therapeutics, Inc.

LRMR
$2.30 ▼ -0.47 (-16.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Larimar Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -220.9% ↘
FCF / Share None
Trailing P/E —
Price / Book 2.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-165.67M
↓ -105.5% —
FCF / Share Free cash flow per share
$-1.16
↓ -51.9% —
Long-Term Debt Long-term obligations
$14.54M
↓ -27.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Cash Quality ↓
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 56 quarters